Found 40 with Last Name = 'gregory' and Initial = 'ma' TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 4.20nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 5.40nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 5.90nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 6.5nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 7.70nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 7.90nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 9.5nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 10nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 10nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 12nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 13nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 18nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 45nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 95nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 180nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 370nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 430nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase FKBP1A(Homo sapiens (Human))
Isomerase Therapeutics Ltd.
US Patent
Isomerase Therapeutics Ltd.
US Patent
Affinity DataKi: 460nMAssay Description:The assay was conducted at 10° C. in 50 mM Tris buffer at pH8.0, 50 μM DTT, 100 mM NaCl, 0.005% NP40 with 6 nM FKBP12 and 60 μM substrate (...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase A(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 0.310nMAssay Description:The PPlase activity of recombinant CypA or D, produced by thrombin cleavage of GST-CypA or D, was determined by following the rate of hydrolysis of N...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase A(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 0.800nMAssay Description:The PPlase activity of recombinant CypA or D, produced by thrombin cleavage of GST-CypA or D, was determined by following the rate of hydrolysis of N...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase A(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 2.40nMAssay Description:The PPlase activity of recombinant CypA or D, produced by thrombin cleavage of GST-CypA or D, was determined by following the rate of hydrolysis of N...More data for this Ligand-Target Pair
TargetPeptidyl-prolyl cis-trans isomerase A(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 9.70nMAssay Description:The PPlase activity of recombinant CypA or D, produced by thrombin cleavage of GST-CypA or D, was determined by following the rate of hydrolysis of N...More data for this Ligand-Target Pair
TargetSolute carrier organic anion transporter family member 1B3(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 130nMpH: 7.3 T: 2°CAssay Description:To assess the inhibition of the OAT1B1 and OAT1B3 uptake transporters, an in vitro uptake transporter assay from Solvo Biotechnology Inc. was used. U...More data for this Ligand-Target Pair
Affinity DataIC50: 180nMT: 2°CAssay Description:To assess the inhibition of the MRP2, MRP3 and BSEP efflux transporters, an in vitro vesicular transporter assay from Solvo Biotechnology Inc. was us...More data for this Ligand-Target Pair
TargetSolute carrier organic anion transporter family member 1B3(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 190nMpH: 7.3 T: 2°CAssay Description:To assess the inhibition of the OAT1B1 and OAT1B3 uptake transporters, an in vitro uptake transporter assay from Solvo Biotechnology Inc. was used. U...More data for this Ligand-Target Pair
TargetSolute carrier organic anion transporter family member 1B1(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 450nMpH: 7.3 T: 2°CAssay Description:To assess the inhibition of the OAT1B1 and OAT1B3 uptake transporters, an in vitro uptake transporter assay from Solvo Biotechnology Inc. was used. U...More data for this Ligand-Target Pair
Affinity DataIC50: 460nMT: 2°CAssay Description:To assess the inhibition of the MRP2, MRP3 and BSEP efflux transporters, an in vitro vesicular transporter assay from Solvo Biotechnology Inc. was us...More data for this Ligand-Target Pair
Affinity DataIC50: 720nMpH: 7.4 T: 2°CAssay Description:To assess the inhibition of the P-glycoprotein (Pgp/MDR1) transporter, an in vitro ATPase assay from Cyprotex was used. MDR1MDCK cells obtained from ...More data for this Ligand-Target Pair
Affinity DataIC50: 730nMpH: 7.4 T: 2°CAssay Description:To assess the inhibition of the P-glycoprotein (Pgp/MDR1) transporter, an in vitro ATPase assay from Cyprotex was used. MDR1MDCK cells obtained from ...More data for this Ligand-Target Pair
TargetSolute carrier organic anion transporter family member 1B1(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 850nMpH: 7.3 T: 2°CAssay Description:To assess the inhibition of the OAT1B1 and OAT1B3 uptake transporters, an in vitro uptake transporter assay from Solvo Biotechnology Inc. was used. U...More data for this Ligand-Target Pair
TargetSolute carrier organic anion transporter family member 1B3(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 1.80E+3nMpH: 7.3 T: 2°CAssay Description:To assess the inhibition of the OAT1B1 and OAT1B3 uptake transporters, an in vitro uptake transporter assay from Solvo Biotechnology Inc. was used. U...More data for this Ligand-Target Pair
TargetATP-binding cassette sub-family C member 2(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 3.10E+3nMT: 2°CAssay Description:To assess the inhibition of the MRP2, MRP3 and BSEP efflux transporters, an in vitro vesicular transporter assay from Solvo Biotechnology Inc. was us...More data for this Ligand-Target Pair
TargetATP-binding cassette sub-family C member 2(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 4.10E+3nMT: 2°CAssay Description:To assess the inhibition of the MRP2, MRP3 and BSEP efflux transporters, an in vitro vesicular transporter assay from Solvo Biotechnology Inc. was us...More data for this Ligand-Target Pair
TargetSolute carrier organic anion transporter family member 1B1(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 4.30E+3nMpH: 7.3 T: 2°CAssay Description:To assess the inhibition of the OAT1B1 and OAT1B3 uptake transporters, an in vitro uptake transporter assay from Solvo Biotechnology Inc. was used. U...More data for this Ligand-Target Pair
Affinity DataIC50: 1.23E+4nMT: 2°CAssay Description:To assess the inhibition of the MRP2, MRP3 and BSEP efflux transporters, an in vitro vesicular transporter assay from Solvo Biotechnology Inc. was us...More data for this Ligand-Target Pair
TargetATP-binding cassette sub-family C member 2(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 1.60E+4nMT: 2°CAssay Description:To assess the inhibition of the MRP2, MRP3 and BSEP efflux transporters, an in vitro vesicular transporter assay from Solvo Biotechnology Inc. was us...More data for this Ligand-Target Pair
Affinity DataIC50: 5.00E+4nMpH: 7.4 T: 2°CAssay Description:To assess the inhibition of the P-glycoprotein (Pgp/MDR1) transporter, an in vitro ATPase assay from Cyprotex was used. MDR1MDCK cells obtained from ...More data for this Ligand-Target Pair
TargetATP-binding cassette sub-family C member 2(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 5.00E+4nMT: 2°CAssay Description:To assess the inhibition of the MRP2, MRP3 and BSEP efflux transporters, an in vitro vesicular transporter assay from Solvo Biotechnology Inc. was us...More data for this Ligand-Target Pair
TargetATP-binding cassette sub-family C member 2(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 5.00E+4nMT: 2°CAssay Description:To assess the inhibition of the MRP2, MRP3 and BSEP efflux transporters, an in vitro vesicular transporter assay from Solvo Biotechnology Inc. was us...More data for this Ligand-Target Pair
TargetATP-binding cassette sub-family C member 2(Homo sapiens (Human))
NEUROVIVE PHARMACEUTICAL AB
US Patent
NEUROVIVE PHARMACEUTICAL AB
US Patent
Affinity DataIC50: 5.00E+4nMT: 2°CAssay Description:To assess the inhibition of the MRP2, MRP3 and BSEP efflux transporters, an in vitro vesicular transporter assay from Solvo Biotechnology Inc. was us...More data for this Ligand-Target Pair
